Optinose Inc. closed an underwritten public offering of 5,750,000 common shares, priced at $22.25 each.
The Yardley, Pa.-based developer of ear, nose, throat and allergy therapies sold 2,875,000 shares, raising about $60.1 million in net proceeds. Certain stockholders sold an equal number of shares and raised the same amount.
Underwriters fully exercised their option to buy additional common shares.
Jefferies and Piper Jaffray acted as lead book-running managers for the offering, with BMO Capital Markets and RBC Capital Markets as joint book-running managers, as well as Cantor as sole lead manager.
